NEW YORK, January 1, 2026, 21:17 ET — Market closed
- Cytokinetics shares last closed up 3.5% at $63.54, ahead of the company’s planned January commercial launch of Myqorzo. 1
- A regulatory filing showed EVP Andrew Callos sold 1,809 shares under a prearranged trading plan. 2
- Investors are watching for U.S. pricing details, early prescriptions and the next earnings update expected in late February. 3
Cytokinetics, Incorporated shares ended Wednesday up 3.5% at $63.54, the final U.S. trading session of 2025, after markets closed Thursday for the New Year’s Day holiday. The stock has traded between $29.31 and $70.98 over the past 52 weeks, according to market data. 1
The year-end move matters because Cytokinetics is weeks away from its first full-scale commercial test. Investors have been valuing the biotech on clinical data and regulatory milestones; the next swing factor is execution in the field.
In mid-December, the company said the U.S. Food and Drug Administration approved Myqorzo (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy, a heart muscle disease that can block blood flow. The drug carries a boxed warning for risk of heart failure and is available only through a Risk Evaluation and Mitigation Strategy (REMS), a safety program that can require additional monitoring. “This is a historic moment for our company and for the patients we serve,” Chief Executive Robert I. Blum said at the time. 4
A Form 4 filing dated Dec. 30 showed Executive Vice President and Chief Commercial Officer Andrew Callos sold 1,809 shares at an average price of $62.44 on Dec. 29. The filing showed Callos still held 51,353 shares after the transaction. 2
The form indicated the sale was made under a Rule 10b5-1 plan, a preset instruction that allows insiders to trade on a schedule set in advance, rather than at their discretion.
Myqorzo is entering a market already served by Bristol Myers Squibb’s Camzyos, with Cytokinetics aiming to carve out share as doctors compare labels, monitoring requirements and real-world tolerability. The company has said it plans to announce U.S. pricing details before the launch. 3
That makes the next few weeks a “tell” for demand: how quickly specialist centers write first prescriptions, what insurers require for coverage, and whether REMS administration proves a speed bump or a manageable step in routine care.
Technically, Cytokinetics is trading close to its 50-day moving average of about $63 and well above its 200-day moving average near $46, levels traders often use to gauge short- and long-term momentum. 5
Outside the U.S., Cytokinetics has pointed to pending regulatory milestones that could affect sentiment in 2026. In Europe, the company said the CHMP backed Myqorzo in December and that a European Commission decision is expected in the first quarter. 6
In China, Cytokinetics said an approval earlier in December triggered a $7.5 million milestone payment from Sanofi under their Greater China licensing deal. 7
The next scheduled financial checkpoint is earnings. Cytokinetics has not confirmed a date, but Zacks Investment Research estimates results on Feb. 26, with a forecast loss of $1.48 per share. 8
Before the next session on Friday, traders will also watch the macro tape. The Institute for Supply Management’s December manufacturing index is due at 10 a.m. ET, a read that can move rates and risk appetite across growth stocks. 9
The next major U.S. data point is the December jobs report on Jan. 9 at 8:30 a.m. ET, which can influence interest-rate expectations that often bleed into biotech valuations. 10
For Cytokinetics, the nearer-term catalysts remain company-specific: a pricing update, first-week prescription trends once Myqorzo ships, and any new regulatory or SEC filings that add clarity around launch execution.
